Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYML-122 Plus Cytarabine in FLT3+ R/R AML
NCT05241093Phase 2Recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Mar 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CHMFL-FLT3-122 in acute myeloid leukemia (AML), sponsored by Tarapeutics Science Inc. Primary endpoints: Objective Response Rate at 24 months and Composite Complete Remission Rate at 24 months. Started Mar 2022; status: recruiting.
02
Drugs
CHMFL-FLT3-122
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05241093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241093.